Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

21-1430

Sigma-Aldrich

Nicotinic acid

SAJ special grade, ≥99.5%

Sinónimos:

3-Picolinic acid, Niacin, Pellagra preventive factor, Pyridine-3-carboxylic acid, Vitamin B3

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C6H5NO2
Número de CAS:
59-67-6
Peso molecular:
123.11
Beilstein/REAXYS Number:
109591
EC Number:
200-441-0
MDL number:
MFCD00006391
UNSPSC Code:
12352005
PubChem Substance ID:
329752092

grade

SAJ special grade

assay

≥99.5%

form

powder

availability

available only in Japan

color

white

mp

236-239 °C (lit.)

solubility

ethanol: 12.5 g/L at 25 °C
water: soluble 180 g/L at 20 °C

density

1.473 g/cm3 at 25 °C

SMILES string

OC(=O)c1cccnc1

InChI

1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

InChI key

PVNIIMVLHYAWGP-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H319

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

379.4 °F - closed cup

flash_point_c

193 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
U7070
U1648
U5032
U2572
U9746

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Beat Müller et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
Paul M Lavigne et al.
Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
E T Bodor et al.
British journal of pharmacology, 153 Suppl 1, S68-S75 (2007-11-27)
Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico